Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands

Leukemia volume 18, pages 2032–2035 (2004)Cite this article

TO THE EDITOR

Approximately 15% of patients with acute lymphoblastic leukemia (ALL) are 10–20 years old at diagnosis. Adolescents with ALL who are 15 years of age or older are treated by pediatricians or hematologists, depending on their referral. The treatment of adolescent patients according to pediatric or adult protocols results in relatively small numbers of this age group in clinical trials. Consequently, limited information about patient characteristics and survival rates of adolescents over 15 years of age is available.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Boissel N, Auclerc MF, Lheritier V, Perel Y, Thomas X, Leblanc T et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003; 21: 774–780.

    Article  Google Scholar 

  2. Abromowitch M, Ochs J, Pui CH, Kalwinsky D, Rivera GK, Fairclough D et al. High-dose methotrexate improves clinical outcome in children with acute lymphoblastic leukemia: St Jude Total Therapy Study X. Med Pediatr Oncol 1988; 16: 297–303.

    Article  CAS  Google Scholar 

  3. Richards S, Gray R, Peto R, Gaynon P, Masera G . Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children. Lancet 1996; 347: 1783–1788.

    Article  Google Scholar 

  4. Toyoda Y, Manabe A, Tsuchida M, Hanada R, Ikuta K, Okimoto Y et al. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol 2000; 18: 1508–1516.

    Article  CAS  Google Scholar 

  5. Dibenedetto SP, Guardabasso V, Ragusa R, Di Cataldo A, Miraglia V, D'Amico S et al. 6-Mercaptopurine cumulative dose: a critical factor of maintenance therapy in average risk childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 1994; 11: 251–258.

    Article  CAS  Google Scholar 

  6. Arico M, Valsecchi MG, Camitta B . Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000; 342: 998–1006.

    Article  CAS  Google Scholar 

  7. Weisdorf DJ, Billett AL, Hannan P, Ritz J, Sallan SE, Steinbuch M et al. Autologous vs unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia. Blood 1997; 90: 2962–2968.

    CAS  PubMed  Google Scholar 

  8. Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K et al. Dexamethasone vs prednisone and daily oral vs weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2003; 101: 3809–3817.

    Article  CAS  Google Scholar 

  9. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97: 1211–1218.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Erasmus MC, Sophia Children's Hospital, Rotterdam, The Netherlands

    J M de Bont & R Pieters

  2. Erasmus MC, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

    B van der Holt

  3. UMC Utrecht, Utrecht, The Netherlands

    A W Dekker

  4. DCOG, The Hague, The Netherlands

    A van der Does-van den Berg & R Pieters

  5. Erasmus MC, Rotterdam, The Netherlands

    P Sonneveld

Authors
  1. J M de Bont
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B van der Holt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A W Dekker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A van der Does-van den Berg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Sonneveld
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Pieters
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Pieters.

Additional information

The full original manuscript in Dutch language has been submitted to ‘het Nederlands Tijdschrift voor Geneeskunde’.

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Bont, J., Holt, B., Dekker, A. et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 18, 2032–2035 (2004). https://doi.org/10.1038/sj.leu.2403538

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403538

This article is cited by

Search

Advanced search

Quick links